Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality

PHASE3CompletedINTERVENTIONAL
Enrollment

709

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

March 9, 2017

Study Completion Date

November 30, 2017

Conditions
Non Small Cell Lung Cancer
Interventions
DIETARY_SUPPLEMENT

melatonin

20 mgs ingested nightly

DIETARY_SUPPLEMENT

placebo

similar to experimental in all ways except for lack of active ingredient

Trial Locations (8)

V1Y 4N7

Kelowna General Hospital, Kelowna

V3R 7P8

Fraser Health, Surrey

B3H 2Y9

QEII Health Sciences Centre/Capital Health, Halifax

L8N 4A6

St. Joseph's/ McMaster University, Hamilton

N6A 5C1

London Health Sciences Centre, London

K1Y 1J7

Ottawa General Hospital, Ottawa

M5G 1Z5

University Health Network, Toronto

G1V 4G5

Institut universitaire de cardiologie et de pneumologie de Québec, Québec

All Listed Sponsors
collaborator

The Ottawa Hospital

OTHER

collaborator

Lotte & John Hecht Memorial Foundation

OTHER

collaborator

Gateway for Cancer Research

OTHER

lead

The Canadian College of Naturopathic Medicine

OTHER

NCT00668707 - Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality | Biotech Hunter | Biotech Hunter